A single combined measurement of high-sensitivity C-reactive protein, LDL-cholesterol and lipoprotein(a) levels in plasma predicts incident cardiovascular events among women over a 30-year follow-up period, according to a new study.

Cardiomyocytes can activate the type I interferon response in the infarct border zone after myocardial infarction, indicating that the type I interferon pathway, in addition to its well-established role in antiviral responses, is also involved in cardiac injury.

New research suggests that the presence of clonal haematopoiesis is unidirectionally associated with the development of atherosclerosis and that colchicine holds potential therapeutic value.

Acute ischaemic stroke induces persistent innate immune memory through epigenetic changes in myeloid progenitors in the bone marrow, and this innate immune training contributes to cardiac remodelling and dysfunction in the long term, according to a new study.

A new small-molecule inhibitor of vasohibins reduces myocardial stiffness and improves diastolic relaxation in a rat model of HFpEF.

A new study indicates that proteins in the sarcomere complex are stochastically removed and degraded and are replaced by newly translated proteins. Sarcomere turnover occurs at a similar rate within cardiomyocytes and across the heart and slows with ageing.

The advent of pulsed-field ablation — a series of ultra-rapid, high-energy pulses that result in non-thermal cell death via electroporation — is revolutionizing the field of atrial fibrillation ablation. Data on first iterations of the technology indicate that safety and efficacy are at least similar to that of thermal ablation but with meaningfully shorter procedure duration.

In this Tools of the Trade article, Jablonska describes the use of proximity-based labelling for the proteomic profiling of novel protein–protein interactions.

In this Tools of the Trade article, Berkeley and Thomson describe the use of a minimally invasive strategy to standardize the induction of myocardial infarction in mice.

Findings from a new study published in Science Immunology suggest that epigenetic changes in haematopoietic stem cells promote the production of pro-inflammatory macrophages and influence their capacity to generate protective macrophage subsets.

Data from the phase IIb MUIR and ARCHES-2 trials show that RNA interference approaches that target either apolipoprotein C-III or ANGPTL3 significantly reduce plasma triglyceride levels in patients with mixed hyperlipidaemia.

Corey McAleese describes the study that identified the presence of metabolic heterogeneity in endothelial cells from different tissues and discusses its relevance to our current understanding of endothelial metabolism.

Milda Folkmanaite and Manuela Zaccolo highlight a study that demonstrates a role for phase-separated condensates of protein kinase A in buffering molecules of cAMP, to illustrate how phase separation of proteins in cardiac cells might contribute to the regulation of cardiac function.

Haemophilia A is caused by variants in the gene that encodes coagulation factor VIII (FVIII). Sequencing of this gene in the 1980s was the initial step in developing replacement therapy with recombinant FVIII, and thereby removing the risk of blood-borne infections from plasma-derived FVIII.

Poscablo and colleagues identify a distinct haematopoietic platelet differentiation pathway that is enriched in ageing mice, which results in platelets that are hyper-reactive compared with canonical platelet populations.

Data from the SEQUOIA-HCM trial show that aficamten, a cardiac myosin inhibitor, increases exercise capacity and improves quality of life in patients with symptomatic obstructive hypertrophic cardiomyopathy.

In patients with type 2 diabetes mellitus and obesity, bariatric metabolic surgery is associated with a lower risk of the incidence of first-ever congestive heart failure than treatment with glucagon-like peptide 1 receptor agonists, according to a new study.

A study in Nature describes a single-cell-type strategy for vascular cell therapies that involves the artificial transplantation of mitochondria to endothelial cells, which promotes mitophagy and facilitates the formation of functional vessels in ischaemic tissue without the need for mesenchymal stromal cell support.

Activation of the bile acid receptor TGR5 inhibits CD36-mediated fatty acid uptake in cardiomyocytes and protects against cardiac lipotoxicity and the development of diabetic cardiomyopathy in mice, according to a new study.

In the AEGIS-II trial, infusion of apolipoprotein A-I to increase cholesterol efflux capacity did not improve outcomes in patients with acute myocardial infarction.

Treatment for periodontal disease might reduce the recurrence of atrial fibrillation (AF) in patients undergoing ablation, suggesting that periodontitis is a modifiable risk factor for AF.

Findings from the ORBITA-COSMIC trial show that treatment of patients with stable coronary artery disease using a coronary sinus reducer improves angina symptoms but does not increase transmural myocardial perfusion.

Data from the DanGer Shock trial demonstrate that implantation of a microaxial flow pump in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock increases the survival rate compared with standard care alone.

Three randomized clinical trials presented at ACC.24 demonstrate that olezarsen and plozasiran, RNA-based therapies that target APOC3, can robustly reduce plasma triglyceride levels in patients with moderate to severe hypertriglyceridaemia.

According to data from the IMPROVE-HCM trial, ninerafaxstat is well tolerated by patients with symptomatic non-obstructive hypertrophic cardiomyopathy and improves exercise performance among those who are most symptomatically limited.

The under-representation of women in cardiovascular clinical trials persists across participant, clinician and research roles. This gap perpetuates health inequity and hampers the generation, translation and implementation of optimal evidence-based care. Urgent action is needed to address barriers, promote diversity, and ensure inclusive trial design and health-care delivery and dissemination, for

In the REDUCE-AMI trial, the use of β-blockers in patients with acute myocardial infarction (MI) who have undergone early coronary angiography and have a preserved left ventricular ejection fraction did not reduce the risk of death or new MI compared with no β-blocker use.

In patients with symptomatic aortic stenosis and a small aortic annulus, a self-expanding valve has similar rates of clinical outcomes at 1 year and lower rates of bioprosthetic dysfunction compared with a balloon-expandable valve.

A new study identifies a group of gut bacteria that can metabolize cholesterol and are associated with lower plasma cholesterol levels.

Assessing atherosclerosis severity is essential for precise patient stratification. Specifically, there is a need to identify patients with residual inflammation because these patients remain at high risk of cardiovascular events despite optimal management of cardiovascular risk factors. Molecular imaging techniques, such as PET, can have an essential role in this context. PET imaging can indicate

After myocardial infarction, the heart secretes small extracellular vesicles with pro-neoplastic properties that can accelerate tumour growth when taken up by cancer cells.